§ 02
Compare
Brand vs brand · efficacy, dose, mechanism, price.
№ 01
Ozempic
Semaglutide · Novo Nordisk
Avg weight loss14.9%
- Dosage range
- 0.25 – 2.0 mg
- Schedule
- Weekly injection
- Indication
- Type 2 Diabetes
- FDA approval
- 2017
- Cash / month
- $968.52
- With insurance
- $25 – $250
- GoodRx coupon
- $892.4
№ 02
Wegovy
Semaglutide · Novo Nordisk
Avg weight loss16.9%
- Dosage range
- 0.25 – 2.4 mg
- Schedule
- Weekly injection
- Indication
- Chronic weight management
- FDA approval
- 2021
- Cash / month
- $1,349.02
- With insurance
- $0 – $300
- GoodRx coupon
- $1,279.5
№ 03
Mounjaro
Tirzepatide · Eli Lilly
Avg weight loss20.9%
- Dosage range
- 2.5 – 15 mg
- Schedule
- Weekly injection
- Indication
- Type 2 Diabetes
- FDA approval
- 2022
- Cash / month
- $1,069.08
- With insurance
- $25 – $573
- GoodRx coupon
- $998.2
№ 04
Zepbound
Tirzepatide · Eli Lilly
Avg weight loss22.5%
- Dosage range
- 2.5 – 15 mg
- Schedule
- Weekly injection
- Indication
- Chronic weight management
- FDA approval
- 2023
- Cash / month
- $1,086.37
- With insurance
- $0 – $550
- GoodRx coupon
- $1,019.9
§ Mechanism note
Semaglutide vs Tirzepatide
Semaglutide (Ozempic, Wegovy) is a single GLP-1 receptor agonist. Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 agonist — it activates a second incretin pathway, which trial data correlates with greater weight reduction at the highest dose tier.